Oncology Nursing Support for Safe and Effective Use of Eribulin in Metastatic Breast Cancer

Oncology Nursing Support for Safe and Effective Use of Eribulin in Metastatic Breast Cancer

Show other versions (1)

Bibliographic Details
Main Authors:	Diana Donovan, Laura Urquhart, Una Hopkins, Sandra Knight, Laura Moore
Format:	Article
Language:	English
Published:	SAGE Publishing 2014-05-01
Series:	Clinical Medicine Insights: Oncology
Online Access:	http://www.la-press.com/oncology-nursing-support-for-safe-and-effective-use-of-eribulin-in-met-article-a4192

Similar Items

Oncology Nursing Support for Safe and Effective Use of Eribulin in Metastatic Breast Cancer
by: Diana Donovan, et al.
Published: (2014-01-01)

Eribulin mesylate in the treatment of metastatic breast cancer
by: Jain S, et al.
Published: (2012-01-01)

Case Studies in the Management of Metastatic Breast Cancer with Eribulin
by: Sharon Wilks, et al.
Published: (2015-01-01)

Case Studies in the Management of Metastatic Breast Cancer with Eribulin
by: Sharon Wilks, et al.
Published: (2015-10-01)

Budget impact of eribulin in metastatic breast cancer in Russian Federation
by: S. K. Zyryanov, et al.
Published: (2018-05-01)

The role of capecitabine and eribulin in the treatment of metastatic HER2-negative metastatic breast cancer
by: I V Kolyadina, et al.
Published: (2018-09-01)

Eribulin for the treatment of metastatic breast cancer: an update on its safety and efficacy
by: Doherty MK, et al.
Published: (2015-01-01)

A Retrospective Evaluation of Eribulin Dosing Schedules in Metastatic Breast Cancer
by: Gagliardo, Camille, et al.
Published: (2016)

Serum microRNA-based prediction of responsiveness to eribulin in metastatic breast cancer.
by: Natsuko Satomi-Tsushita, et al.
Published: (2019-01-01)

Eribulin Efficacy on Brain Metastases in Heavily Pretreated Patients with Metastatic Breast Cancer
by: Renaud Sabatier, et al.
Published: (2021-03-01)

Eribulin mesylate as a microtubule inhibitor for treatment of patients with metastatic breast cancer
by: Mu&ntilde;oz-Couselo E, et al.
Published: (2011-11-01)

Eribulin for the treatment of metastatic breast cancer: an update on its safety and efficacy [Corrigendum]
by: Doherty MK, et al.
Published: (2015-04-01)

Molecular correlates of response to eribulin and pembrolizumab in hormone receptor-positive metastatic breast cancer
by: Tanya E. Keenan, et al.
Published: (2021-09-01)

CLINICAL ECONOMIC ANALYSIS OF USING ERIBULIN (HALAVEN®) FOR TREATMENT OF PATIENTS WITH METASTATIC BREAST CANCER
by: S. L. Plavinsky, et al.
Published: (2016-02-01)

Economic evaluation of eribulin as second-line treatment for metastatic breast cancer in South Korea
by: Tremblay G, et al.
Published: (2016-09-01)

Outcome of eribulin as a late treatment line for Thai metastatic breast cancer patients
by: Ditsatham C, et al.
Published: (2018-07-01)

Clinical benefit of treatment with eribulin mesylate for metastatic triple‐negative breast cancer: Long‐term outcomes of patients treated in the US community oncology setting
by: Sarah S. Mougalian, et al.
Published: (2018-09-01)

Identification of predictive markers of the therapeutic effect of eribulin chemotherapy for locally advanced or metastatic breast cancer
by: Shinichiro Kashiwagi, et al.
Published: (2017-08-01)

Eribulin (Halaven): a new, effective treatment for women with heavily pretreated metastatic breast cancer
by: Twelves C, et al.
Published: (2011-08-01)

Effectiveness and healthcare costs of eribulin versus capecitabine among metastatic breast cancer patients in Taiwan
by: Yu-Ju Lin, et al.
Published: (2021-06-01)

Successfully treatment by eribulin in visceral crisis: a case of lymphangitic carcinomatosis from metastatic breast cancer
by: Jean-David Fumet, et al.
Published: (2018-08-01)

Phase I clinical trial of the combination of eribulin and everolimus in patients with metastatic triple-negative breast cancer
by: Jin Sun Lee, et al.
Published: (2019-11-01)

The improvement in overall survival for patients with metastatic breast cancer treated with eribulin: the resolution based on results of the expert council
by: V S Andrianova, et al.
Published: (2015-03-01)

Experience of eribulin application in previously treated patients with metastatic or locally recurrent breast cancer under the clinical trial
by: F Sh Ahmetzanov, et al.
Published: (2014-09-01)

Eribulin in Cancer Treatment
by: Umang Swami, et al.
Published: (2015-08-01)

Real-world effectiveness of eribulin in heavily pretreated patients with metastatic breast cancer in China: a multicenter retrospective study
by: Yannan Zhao, et al.
Published: (2021-07-01)

Cost Effectiveness Analysis of Eribulin Mesylate as a Treatment for Metastatic Breast Cancer in Spain: Management in the Later Line of Therapy
by: Gabriel Tremblay, et al.

The results of the first retrospective data analysis of eribulin application in patients with metastatic breast cancer in actual clinical practice in Russia
by: L V Bolotina, et al.
Published: (2016-09-01)

Prospective Analysis of Patients with Metastatic Breast Cancer receiving Eribulin Mesylate as Second or More Lines of Chemotherapy: An Indian Experience
by: BJ Srinivasa, et al.
Published: (2018-06-01)

Stathmin dynamics modulate the activity of eribulin in breast cancer cells
by: Mikihiro Yoshie, et al.
Published: (2021-08-01)

Eribulin mesylate use as third-line therapy in patients with metastatic breast cancer (VESPRY): a prospective, multicentre, observational study
by: Vincenzo Adamo, et al.
Published: (2019-12-01)

Efficacy and safety of eribulin in patients with locally advanced or metastatic breast cancer not meeting trial eligibility criteria: a retrospective study
by: Sakura Iizumi, et al.
Published: (2017-12-01)

Eribulin in the Management of Advanced Breast Cancer: Implications of Current Research Findings
by: Victor C. Kok
Published: (2015-01-01)

Inhibitory effects of iron depletion plus eribulin on the breast cancer microenvironment
by: Wataru Goto, et al.
Published: (2020-12-01)

Eribulin in the Management of Advanced Breast Cancer: Implications of Current Research Findings
by: Victor C. Kok
Published: (2015-12-01)

Utilities of metastatic breast cancer patients treated with taxanes compared to utilities of oncology nurses
by: Hauser, Robert Sean, 1972-
Published: (2011)

Eribulin drug review
by: Nishitha Shetty, et al.
Published: (2014-01-01)

Network meta-analysis of eribulin versus other chemotherapies used as second- or later-line treatment in locally advanced or metastatic breast cancer
by: Qi Zhao, et al.
Published: (2021-06-01)

Efficacy and safety of eribulin in HER2-negative metastatic breast cancer: the results of long-term experience in real clinical practice in Russia
by: Vera A Gorbunova, et al.
Published: (2019-03-01)

Health-related quality of life in patients receiving first-line eribulin mesylate with or without trastuzumab for locally recurrent or metastatic breast cancer
by: Lee Schwartzberg, et al.
Published: (2019-06-01)